Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.


Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.




This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Study Status: Terminated


Condition Intervention Phase
NSCLC Drug: paclitaxel
Drug: paclitaxel poliglumex
Phase 3

Verified by Cell Therapeutics February, 2007

Sponsored by: Cell Therapeutics
Information provided by: Cell Therapeutics identifier: NCT00269828

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

The Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site